{"organizations": [], "uuid": "5c2b2098063e7b8b4e49955f13501bee5877edd0", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180410.html", "section_title": "Archive News &amp; Video for Tuesday, 10 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/mylan-nl-mapi/mylan-buys-marketing-rights-to-ms-treatment-from-israels-mapi-pharma-idUSL3N1RN4GB", "country": "US", "domain_rank": 408, "title": "Mylan buys marketing rights to MS treatment from Israel's Mapi Pharma", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.008, "site_type": "news", "published": "2018-04-10T19:47:00.000+03:00", "replies_count": 0, "uuid": "5c2b2098063e7b8b4e49955f13501bee5877edd0"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/mylan-nl-mapi/mylan-buys-marketing-rights-to-ms-treatment-from-israels-mapi-pharma-idUSL3N1RN4GB", "ord_in_thread": 0, "title": "Mylan buys marketing rights to MS treatment from Israel's Mapi Pharma", "locations": [], "entities": {"persons": [{"name": "tamara mathias", "sentiment": "none"}, {"name": "shounak dasgupta", "sentiment": "none"}], "locations": [{"name": "israel", "sentiment": "none"}, {"name": "bengaluru", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "mylan", "sentiment": "negative"}, {"name": "mylan nv", "sentiment": "negative"}, {"name": "mapi pharma", "sentiment": "negative"}, {"name": "mapi pharma ltd", "sentiment": "none"}, {"name": "ga depot", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 10 (Reuters) - Drugmaker Mylan NV is acquiring global marketing rights to an experimental multiple sclerosis treatment from Israelâ€™s Mapi Pharma Ltd, the companies said on Tuesday.\nBoth companies will partner on the development and commercialization of GA Depot, a long-acting injection used once a month, for the treatment of patients with a type of multiple sclerosis. (Reporting by Tamara Mathias in Bengaluru; Editing by Shounak Dasgupta)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-10T19:47:00.000+03:00", "crawled": "2018-04-11T18:09:41.008+03:00", "highlightTitle": ""}